Clinical Guidelines and Standards Guidelines by Clinical Area

Consensus on infertility treatment related to polycystic ovary syndrome

Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group

Published March 2008 Fertility and Sterility, 89(3), 505-522
DOI 10.1016/j.fertnstert.2007.09.041

RRM Academy Synopsis

Consensus keeps clomiphene first-line for PCOS ovulation induction

Experts agreed in a 2008 consensus that clomiphene remains the recommended first choice to start ovulation in polycystic ovary syndrome (PCOS). Before any treatment, they advise counseling ahead of pregnancy on smoking, alcohol and, for overweight women, weight loss and exercise. The group adds that even singleton PCOS pregnancies are linked to higher health risk for mother and fetus.

Key Findings

  • Ovulation induction by clomiphene citrate and then gonadotropins, hormones injected to stimulate the ovaries, is reported to be highly effective, with 72% as its cumulative singleton live-birth rate.
  • When clomiphene citrate, an anti-estrogen, fails to result in pregnancy, the recommended second-line step is gonadotropin injections or laparoscopic ovarian surgery, and the group names IVF as the third-line step.
  • Used alone, laparoscopic (keyhole) ovarian surgery is usually effective for less than 50% of women, and when it is not, additional ovulation induction medication is required.
  • The group links gonadotropin use with increased chances of multiple pregnancy and says that such use therefore requires intense monitoring of how the ovaries respond.
  • The group holds that metformin should be limited to women with glucose intolerance and does not recommend its routine use in ovulation induction.

Interpretation

The synopsis rests on the published abstract of a 2008 consensus statement. A consensus statement sets out what a panel of experts agreed, based on the evidence they had at the time. The European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine sponsored the workshop. The advice is aimed at infertile women with PCOS. The group found too little evidence to back routine use of aromatase inhibitors to start ovulation. The authors call for ovulation induction tailored to each woman's screening results, which may depart from the first-, second- and third-line sequence for well-defined groups of women.

RRM Context

PCOS, now also named PMOS (Polyendocrine Metabolic Ovarian Syndrome), is a hormone and metabolic condition. RRM seeks its cause in each woman and evaluates both partners before any treatment. The group's call to tailor ovulation induction to each woman's screening results shares that focus. IVF, the third step in this consensus, bypasses the ovulation problem without treating its cause.

Abstract

The treatment of infertile women with polycystic ovary syndrome (PCOS) is surrounded by many controversies. On the basis of the currently available evidence, a group of experts reached a consensus regarding the therapeutic challenges raised in these women. Before any intervention is initiated, preconceptional counseling should be provided emphasizing the importance of lifestyle, especially weight reduction and exercise in overweight women, smoking, and alcohol consumption. The recommended first-line treatment for ovulation induction remains the anti-estrogen clomiphene citrate (CC). Recommended second-line intervention, should CC fail to result in pregnancy, is either exogenous gonadotropins or laparoscopic ovarian surgery (LOS). The use of exogenous gonadotropins is associated with increased chances for multiple pregnancy, and, therefore, intense monitoring of ovarian response is required. Laparoscopic ovarian surgery alone is usually effective in less than 50% of women, and additional ovulation induction medication is required under those circumstances. Overall, ovulation induction (representing the CC-gonadotropin paradigm) is reported to be highly effective with a cumulative singleton live-birth rate of 72%. Recommended third-line treatment is in vitro fertilization (IVF). More patient-tailored approaches should be developed for ovulation induction based on initial screening characteristics of women with PCOS. Such approaches may result in deviation from the above mentioned first-line, second-line, or third-line ovulation strategies in well-defined subsets of patients. Metformin use in PCOS should be restricted to women with glucose intolerance. Based on recent data available in the literature, the routine use of this drug in ovulation induction is not recommended. Insufficient evidence is currently available to recommend the clinical use of aromatase inhibitors for routine ovulation induction. Even singleton pregnancies in PCOS are associated with increased health risk for both the mother and the fetus.

Topics

Related research

Clinical Guidelines and Standards › Guidelines by Clinical Area › Fertility and Infertility Guidelines · Therapeutics › Ovulation Agents › Selective Estrogen Receptor Modulators · Infertility › Ovulation Induction › Clomiphene Citrate
DOI 10.1016/j.fertnstert.2007.09.041 10.1016/j.fertnstert.2007.09.041 Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group et al. 2008, Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2008